Mr. Hill Meade will manage the company’s information services and technology.
CHALFONT, PA – August 16, 2012 – Genomind, a personalized medicine company comprised of innovative researchers and expert leaders in psychiatry and neurology, today announced the addition of Hill Meade as Senior Vice President, Information Services & Technology. Mr. Meade brings more than 30 years of extensive IT and healthcare experience to Genomind.
“Hill’s background both in the healthcare industry and in every facet of IT management makes him an ideal candidate to join the Genomind team,” said Scott A. Storrer, President and CEO of Genomind. “His wealth of knowledge and proven experience are impressive, and we are excited to have him join our executive staff.”
Mr. Meade has worked in strategy development, operations management, system requirements definition, systems development life cycle, process assessment/redesign, and project management. Prior to joining Genomind, he held executive titles at MEDecision, Siemens Healthcare, and Deloitte Consulting’s Healthcare and Insurance IT practice. A member of the Healthcare Financial Management Association and America’s Health Insurance Plans, Mr. Meade is also a Project Management Professional and a member of the Project Management Institute.
“I am honored to work for a company as innovative and dynamic as Genomind, and I look forward to helping them create and deliver advanced technology to bring their innovative products and future developments to a fast-paced industry” said Mr. Meade. “Genomind is forward-thinking and focused on advancing the mental health field, and I am prepared to emulate those traits as I manage and enhance our technology platform.”
About the Genecept™ Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/products/assay.
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
For more information, contact:
Marketing Manager, Genomind